Given the scalability of DNA manufacturing and ease of DNA delivery relative to conventional recombinant
protein monoclonal antibody therapies, the DMAb platform has potential to greatly expand the market for monoclonal antibody prophylaxis / therapy against challenging infectious disease targets.
The company tested that potential
therapy, a type of
protein known as a
monoclonal antibody, on mice with their own form of FOP and lo and behold, they stopped growing unwelcome new bone.
He has been a founder or co-founder of several biotechnology companies and his work has included
protein therapeutics (Receptor BioLogix, Inc., 2003 - 2008), small molecules (NewBiotics, Inc., 1997 - 2002), gene
therapy (Canji, Inc. / Schering - Plough Corporation, 1992 - 1997), and
monoclonal antibody therapeutics (Genentech, Inc. 1980 - 1992).